close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

10.62 -0.16 (-1.48%)
Streaming Delayed Price Updated: 9:45 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Emergent BioSolutions Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
From FN Media Group LLC
Via GlobeNewswire
News headline image
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Participate in Upcoming Investor Conferences
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports First Quarter 2025 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Stock Repurchase Program
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Separately, Company leaders will attend and present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025 
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
From Emergent BioSolutions
Via GlobeNewswire
News headline image
Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts
From Emergent BioSolutions
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today